Jazz Pharmaceuticals plc (JAZZ) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.23B USD | Liabilities, Current |
| Cash and equivalents | 1.62B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 880.90M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 443.00M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.23B | $1.62B | (m) | $880.90M | $443.00M | (m) |
| 2026-03-31 | (m) | $2.25B | $1.84B | (m) | $836.30M | $437.50M | (m) |
| 2025-12-31 | (m) | $2.24B | $1.39B | (m) | $830.75M | $416.96M | (m) |
| 2025-09-30 | (m) | $2.27B | $1.33B | (m) | $764.36M | $483.11M | (m) |
| 2025-06-30 | (m) | $2.07B | $1.19B | (m) | $714.00M | $504.99M | (m) |
| 2025-03-31 | (m) | $1.22B | $1.86B | (m) | $652.99M | $492.78M | (m) |
| 2024-12-31 | (m) | $1.04B | $2.41B | (m) | $716.76M | $480.44M | (m) |
| 2024-09-30 | (m) | $1.03B | $2.22B | (m) | $723.64M | $539.30M | (m) |
| 2024-06-30 | (m) | $1.56B | $1.36B | (m) | $698.04M | $542.55M | (m) |
| 2024-03-31 | (m) | $1.56B | $1.44B | (m) | $707.10M | $577.32M | (m) |
| 2023-12-31 | (m) | $1.54B | $1.51B | (m) | $705.79M | $597.04M | (m) |
| 2023-09-30 | (m) | $1.57B | $1.34B | (m) | $627.84M | $611.83M | (m) |
| 2023-06-30 | (m) | $945.26M | $1.28B | (m) | $610.39M | $657.21M | (m) |
| 2023-03-31 | (m) | $908.90M | $1.17B | (m) | $623.94M | $674.78M | (m) |
| 2022-12-31 | (m) | $933.19M | $881.48M | (m) | $651.49M | $714.06M | (m) |
| 2022-09-30 | (m) | $812.95M | $839.36M | (m) | $601.18M | $728.07M | (m) |
| 2022-06-30 | (m) | $705.44M | $711.26M | (m) | $594.03M | $861.71M | (m) |
| 2022-03-31 | (m) | $737.41M | $490.83M | (m) | $572.39M | $985.45M | (m) |
| 2021-12-31 | (m) | $809.30M | $591.45M | (m) | $563.36M | $1.07B | (m) |
| 2021-09-30 | (m) | $735.05M | $671.78M | (m) | $499.02M | $1.14B | (m) |
| 2021-06-30 | (m) | $880.59M | $891.40M | (m) | $506.66M | $1.25B | (m) |
| 2021-03-31 | (m) | $752.09M | $2.10B | (m) | $413.98M | $115.47M | (m) |
| 2020-12-31 | (m) | $653.75M | $1.06B | (m) | $396.49M | $95.40M | (m) |
| 2020-09-30 | (m) | $642.13M | $741.94M | (m) | $361.66M | $91.40M | (m) |
| 2020-06-30 | (m) | $409.96M | $786.08M | (m) | $351.92M | $92.53M | (m) |
| 2020-03-31 | (m) | $396.12M | $701.60M | (m) | $317.30M | $85.61M | (m) |
| 2019-12-31 | (m) | $364.49M | $637.34M | (m) | $355.99M | $78.61M | (m) |
| 2019-09-30 | (m) | $390.44M | $795.17M | (m) | $267.03M | $71.11M | (m) |
| 2019-06-30 | (m) | $369.49M | $637.74M | (m) | $311.25M | $69.00M | (m) |
| 2019-03-31 | (m) | $414.00M | $547.47M | (m) | $320.49M | $60.71M | (m) |
| 2018-12-31 | (m) | $345.49M | $309.62M | (m) | $263.84M | $52.96M | (m) |
| 2018-09-30 | (m) | $341.29M | $499.02M | (m) | $279.44M | $43.44M | (m) |
| 2018-06-30 | (m) | $347.95M | $485.08M | (m) | $278.44M | $46.16M | (m) |
| 2018-03-31 | (m) | $375.62M | $453.17M | (m) | $281.42M | $46.38M | (m) |
| 2017-12-31 | (m) | $293.95M | $386.04M | (m) | $224.13M | $43.24M | (m) |
| 2017-09-30 | (m) | $268.18M | $252.62M | (m) | $258.62M | $41.34M | (m) |
| 2017-06-30 | (m) | $250.39M | $239.21M | (m) | $238.75M | $39.66M | (m) |
| 2017-03-31 | (m) | $392.77M | $347.00M | (m) | $243.03M | $37.65M | (m) |
| 2016-12-31 | (m) | $257.41M | $365.96M | (m) | $234.24M | $34.05M | (m) |
| 2016-09-30 | (m) | $232.86M | $366.57M | (m) | $238.07M | $32.35M | (m) |
| 2016-06-30 | (m) | $226.72M | $867.97M | (m) | $231.84M | $33.29M | (m) |
| 2016-03-31 | (m) | $398.83M | $979.78M | (m) | $223.80M | $25.37M | (m) |
| 2015-12-31 | (m) | $226.64M | $988.78M | (m) | $209.69M | $19.45M | (m) |
| 2015-09-30 | (m) | $340.19M | $998.86M | (m) | $195.82M | $30.02M | (m) |
| 2015-06-30 | (m) | $225.16M | $921.64M | (m) | $193.65M | $30.78M | (m) |
| 2015-03-31 | (m) | $220.58M | $782.60M | (m) | $189.68M | $30.69M | (m) |
| 2014-12-31 | (m) | $216.80M | $684.04M | (m) | $186.37M | $30.04M | (m) |
| 2014-09-30 | (m) | $223.74M | $575.04M | (m) | $187.60M | $37.61M | (m) |
| 2014-06-30 | (m) | $197.77M | $268.25M | (m) | $160.78M | $33.10M | (m) |
| 2014-03-31 | (m) | $238.01M | $245.87M | (m) | $154.99M | $36.99M | (m) |
| 2013-12-31 | (m) | $204.03M | $636.50M | (m) | $124.81M | $28.67M | (m) |
| 2013-09-30 | (m) | $203.36M | $588.46M | (m) | $113.27M | $24.87M | (m) |
| 2013-06-30 | (m) | $184.35M | $504.31M | (m) | $114.08M | $28.13M | (m) |
| 2013-03-31 | (m) | $243.72M | $450.51M | (m) | $93.83M | $22.83M | (m) |
| 2012-12-31 | $462.68M | $191.54M | $387.20M | $0.00 | $75.48M | $26.52M | 2.42× |
| 2012-09-30 | $278.10M | $178.57M | $189.79M | $0.00 | $88.30M | $30.30M | 1.56× |
| 2012-06-30 | (m) | $192.32M | $154.54M | (m) | $78.13M | $48.35M | (m) |
| 2012-03-31 | $300.36M | $104.58M | $170.65M | $73.56M | $56.14M | $16.99M | 2.87× |
| 2011-12-31 | $192.27M | $52.87M | $82.08M | $75.82M | $34.37M | $3.91M | 3.64× |
| 2011-09-30 | $144.78M | $57.53M | $101.22M | $12.13M | $31.43M | $4.30M | 2.52× |
| 2011-06-30 | (m) | $81.32M | $102.40M | (m) | $25.00M | $4.74M | (m) |
| 2011-03-31 | (m) | (m) | $65.06M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $59.94M | $44.79M | (m) | $22.08M | $5.05M | (m) |
| 2010-09-30 | (m) | (m) | $22.85M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $9.57M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $15.60M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $24.90M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |